Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766960 · ClinicalTrials.gov registry record · Phase 1
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01766960 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 22 participants.
The verdict
NCT01766960, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
One-third of the U.S. population suffers from non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by diabetes and obesity, and is becoming more common. Although many people have this disease, the change in how the liver handles drugs and compounds in the body has not been studied. The purpose of this study is to investigate how advanced NAFLD changes the ability of the liver to handle both endogenous and exogenous compounds.
Interventions
- DRUG Morphine
- OTHER High fat meal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01766960
The ClinicalTrials.gov registry entry for NCT01766960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Morphine is the first listed.
NCT01766960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01766960 about?
NCT01766960 is a clinical study titled "Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease". One-third of the U.S. population suffers from non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by diabetes and obesity, and is becoming more common. Although many people have this disease, the change in how the liver handles drugs and compounds in the body has not been studied. The purpose...
What is the current status of trial NCT01766960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2012-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01766960?
The interventions under investigation include: Morphine (DRUG), High fat meal (OTHER).
Who is sponsoring clinical trial NCT01766960?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.